Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Rating of “Moderate Buy” from Analysts

Tempus AI, Inc. (NASDAQ:TEM) has earned an average recommendation of “Moderate Buy” from the twelve analysts that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $58.55.

Several research firms have recently commented on TEM. Piper Sandler reaffirmed a “neutral” rating and set a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the company from $45.00 to $65.00 in a research note on Monday, November 11th. TD Cowen restated a “buy” rating and issued a $74.00 target price (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Loop Capital reduced their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Finally, Bank of America boosted their price objective on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th.

Tempus AI Price Performance

Tempus AI stock opened at $68.09 on Wednesday. The stock’s 50 day simple moving average is $50.29 and its two-hundred day simple moving average is $51.82. Tempus AI has a fifty-two week low of $22.89 and a fifty-two week high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Insider Transactions at Tempus AI

In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the sale, the insider now owns 16,164,449 shares of the company’s stock, valued at $694,263,084.55. This represents a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric P. Lefkofsky sold 476,209 shares of Tempus AI stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $49.84, for a total value of $23,734,256.56. Following the completion of the sale, the chief executive officer now directly owns 6,502,643 shares of the company’s stock, valued at approximately $324,091,727.12. This represents a 6.82 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,583,467 shares of company stock valued at $130,542,311.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Kovitz Investment Group Partners LLC bought a new stake in shares of Tempus AI in the 3rd quarter worth approximately $1,367,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Tempus AI in the fourth quarter worth $1,091,000. Sumitomo Mitsui Trust Group Inc. increased its stake in Tempus AI by 1,591.2% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after acquiring an additional 1,145,698 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Tempus AI in the 4th quarter valued at approximately $178,000. Finally, Captrust Financial Advisors acquired a new stake in Tempus AI during the 3rd quarter valued at $2,726,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.